Cd279 pd1 clone eh12.2h7

Manufactured by BioLegend

Sourced in United States

CD279 (PD1; clone EH12.2H7) is an antibody that binds to the PD-1 receptor. PD-1 is an inhibitory receptor expressed on activated T cells, B cells, and myeloid cells. The clone EH12.2H7 is commonly used to detect and study PD-1 expression.

Automatically generated - may contain errors

Lab products found in correlation

Cd49d clone 9f10, by BioLegend (1 mentions) Live dead fixable aqua dead cell stain kit, by Thermo Fisher Scientific (1 mentions) Lsrfortessa, by BD (1 mentions) Cd3 clone sp34 2, by BD (1 mentions) Cd8 sk1, by BD (1 mentions) Cxcr5 mu5ubee, by Thermo Fisher Scientific (1 mentions) Cd28 cd28.2, by Thermo Fisher Scientific (1 mentions) Cd95 dx2, by BD (1 mentions) Ki67 b56, by BD (1 mentions) Cd4 l200, by BD (1 mentions) Perforin pf 344, by Mabtech (1 mentions) Hla dr l243, by BioLegend (1 mentions) Tnfα mab11, by BD (1 mentions) Il 2 mq1 17h12, by BD (1 mentions)

Close spelling variants of this product

EH12.2H7 (13 citations) Clone EH12.2H7 (5 citations) CD279 (clone EH12.2H7) (2 citations)

2 protocols using cd279 pd1 clone eh12.2h7

Trafficking Molecule Expression in T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

CTL (1.5 × 10⁶) were stained for molecules that modulate T cell trafficking, including CD49d (clone 9F10; BioLegend, San Diego, CA, USA), CD162 (PSGL-1; clone KPL-1; BioLegend), CD183 (CXCR3; clone 1C6/CXCR3; BD Biosciences), and CD195 (CCR5; clone 2D7/CCR; BD), as well as molecules involved in co-stimulation/inhibition, including CD137 (41BB; clone 5F4; BioLegend), CD279 (PD1; clone EH12.2H7; BioLegend), and CD357 (GITR; eBioAITR; eBioscience, San Diego, CA), within 2 hours after fucosylation. The LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit (Life Technologies, Eugene, OR) was used to assess cell viability. Flow cytometry was done on live cells using a BD LSR Fortessa, and data was analyzed using FlowJo software (FlowJo, Ashland, OR).

Alatrash G., Qiao N., Zhang M., Zope M., Perakis A.A., Sukhumalchandra P., Philips A.V., Garber H.R., Kerros C., John L.S., Khouri M.R., Khong H., Clise-Dwyer K., Miller L.P., Wolpe S., Overwijk W.W., Molldrem J.J., Ma Q., Shpall E.J, & Mittendorf E.A. (2019). Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-specific Cytotoxic T Lymphocytes. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(8), 2610-2620.

+ Open protocol

+ Expand

Multi-Marker Immune Profiling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies used in this study are as follows: CD3 (clone SP-34–2; BD Biosciences), CXCR5 (MU5UBEE; eBioscience), GagCM9 tetramer (NIH tetramer core), CD28 (CD28.2; eBioscience), CD95 (DX2; BD Biosciences), CD279 (PD-1; clone EH12.2H7; BioLegend), CD8 (SK1; BD Bioscience), Ki67 (B56; BD Biosciences), CD4 (L200; BD Biosciences), GrzB (GB11; BD Biosciences), perforin (Pf-344; Mabtech), FoxP3 (206D; BioLegend), HLA-DR (L243; BioLegend), IFNλ (B27; BD Biosciences), TNFα (MAb11; BD Biosciences), and IL-2 (MQ1- 17H12; BD Biosciences).

Rahman S.A., Yagnik B., Bally A.P., Morrow K.N., Wang S., Vanderford T.H., Freeman G.J., Ahmed R, & Amara R.R. (2021). PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue. Science immunology, 6(63), eabh3034.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!